Zur klinischen Relevanz des Interleukin-6 und -18, 17β-Estradiol (E₂) und des Serumoxalats für das aktuelle biochemische Monitoring beim Mammakarzinom

 

 Buy Article Permissions and Reprints

Zusammenfassung

Fragestellung: Die Serumkonzentration verschiedener biochemischer Marker (Zytokine, NO, Oxalat, Steroide) wurde im Hinblick auf den klinischen Status der Erkrankung bewertet. Es wurde untersucht, ob unterschiedliche Konzentrationsverläufe während der verschiedenen Stadien des Mammakarzinoms vorlagen. Material und Methodik: Serumproben von 54 Patientinnen der Klinik für Frauenheilkunde und Geburtshilfe wurden untersucht. Die Oxalatkonzentration wurde mit einer Chemilumineszenz-(CL-)Methode bestimmt, IL-6 und -18 mit einem ELISA und E₂ mit einem kompetitiven Immunoassay unter Anwendung des direkten Chemilumineszenzverfahrens. Die statistische Auswertung erfolgte mit SPSS Version 17.0. Ergebnisse: Oxalat: tumorfrei (tf) (x¯ = 20,88 µmol/l)/1–2 Metastasenlokalisationen (ML) (x¯ = 20,16 µmol/l) p = 0,7; tf/3–4 ML (x¯ = 16,24 µmol/l) p = 0,033; 1–2 ML/3–4 ML p = 0,091. IL-6: tf (x¯ = 0,13 pg/ml)/1–2 ML (x¯ = 6,97 pg/ml) p < 0,0005; tf/3–4 ML (x¯ = 10,00 pg/ml) p < 0,0005; 1–2 ML/3–4 ML p = 0,045. IL-18: tf (x¯ = 297,45 pg/ml)/1–2 ML (x¯ = 295,19 pg/ml) p = 0,96; tf/3–4 ML (x¯ = 403,81 pg/ml) p = 0,20; 1–2 ML/3–4 ML p = 0,17. Estrogen: tf (x¯ = 53,86 pg/ml)/1–2 ML (x¯ = 31,54 pg/ml) p = 0,96; tf/3–4 ML (x¯ = 19,39 pg/ml) p = 0,20; 1–2 ML/3–4 ML p = 0,17. Schlussfolgerung: Oxalat, IL-6 und IL-18 erweisen sich als potenzielle Kandidaten für ein erweitertes biochemisches Monitoring des Mammakarzinoms.

Abstract

Purpose: To assess clinical manifestations of breast cancer we evaluated blood levels of oxalate, IL-6, IL-18 and estrogen. We aimed to reveal a correlation between blood levels and disease stage. Material and Methods: Blood samples were taken from 54 patients who presented to the Clinic for Gynecology and Obstetrics. Oxalate concentrations were measured by chemiluminescence, IL-6 and -18 levels with ELISA and estrogen by competitive immunoassay. Statistical analysis was done using SPSS version 17.0. Results: Oxalate: tf (x¯ = 20.88 µmol/l)/1–2 ML (x¯ = 20.16 µmol/l) p = 0.7; tf/3–4 ML (x¯ = 16.24 µmol/l) p = 0.033; 1–2 ML/3–4 ML p = 0.091. IL-6: tf (x¯ = 0.13 pg/ml)/1–2 ML (x¯ = 6.97 pg/ml) p < 0.0005; tf/3–4 ML (x¯ = 10.00 pg/ml) p < 0.0005; 1–2 ML/3–4 ML p = 0.045. IL-18: tf (x¯ = 297.45 pg/ml)/1–2 ML (x¯ = 295.19 pg/ml) p = 0.96; tf/3–4 ML (x¯ = 403.81 pg/ml) p = 0.20; 1–2 ML/3–4 ML p = 0.17. Estrogen: tf (x¯ = 53.86 pg/ml)/1–2 ML (x¯ = 31.54 pg/ml) p = 0.96; tf/3–4 ML (x¯ = 19.39 pg/ml) p = 0.20; 1–2 ML/3–4 ML p = 0.17. Conclusion: Oxalate, IL-6 and IL-18 are potential candidates for a better biochemical management of breast cancer.

Literatur

• 1 Kamangar F, Dores G M, Anderson W F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world.  J Clin Oncol. 2006;  24 2137-2150
  CrossrefPubMedGoogle Scholar
• 2 Robert Koch Institute eds.. Cancer in Germany, 2003 – 2004. Incidence and Trends. 6th revised edition. Berlin: Robert Koch Institute; 2008
  Google Scholar
• 3 Catarino R, Ferreira M M, Rodrigues H et al. Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer.  DNA Cell Biol. 2008;  27 415-421
  CrossrefPubMedGoogle Scholar
• 4 Boros L G, Brackett D J, Harrigan G G. Metabolic biomarker and kinase drug target discovery in cancer using stable isotope-based dynamic metabolic profiling (SIDMAP).  Curr Cancer Drug Targets. 2003;  3 445-453
  CrossrefPubMedGoogle Scholar
• 5 Albrecht S. Determination of serum oxalate using peroxyoxalate chemiluminescence of free oxalic acid.  J Biolumin Chemilumin. 1993;  8 21-24
  CrossrefPubMedGoogle Scholar
• 6 Morgan M, Cooke M, Christopherson P et al. Calcium hydroxyapatite promotes mitogenesis and matrix metalloproteinase expression in human breast cancer cell lines.  Mol Carcinog. 2001;  32 111-117
  CrossrefPubMedGoogle Scholar
• 7 Going J J, Anderson T J, Crocker P R et al. Weddellite calcification in the breast: eighteen cases with implications for breast cancer screening.  Histopathology. 1990;  16 119-124
  PubMedGoogle Scholar
• 8 Morgan M P, Cooke M M, McCarthy G M. Microcalcifications associated with breast cancer: an epiphenomenon of biologically significant feature of selected tumors?.  J Mammary Gland Biol Neoplasia. 2005;  10 181-187
  CrossrefPubMedGoogle Scholar
• 9 Froung C, Meunier M, Guinebretiere J et al. Polyhedral microcalcifications at mammography: Histological correlation with calcium oxalate.  Radiology. 1993;  186 681-684
  PubMedGoogle Scholar
• 10 Boros L G, Brackett D J, Harrigan G G. Metabolic biomarker and kinase drug target discovery in cancer using stable isotope-based dynamic metabolic profiling (SIDMAP).  Curr Cancer Drug Targets. 2003;  3 445-453
  CrossrefPubMedGoogle Scholar
• 11 Albrecht S. Oxalat – tatsächlich nur ein humanes Stoffwechsel-Endprodukt?.  Angew Chem. 1994;  106 1864-1865
  CrossrefPubMedGoogle Scholar
• 12 Conze D, Weiss L, Regen P S et al. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells.  Cancer Res. 2001;  61 8851-8858
  PubMedGoogle Scholar
• 13 Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?.  Lancet. 2001;  357 539-545
  CrossrefPubMedGoogle Scholar
• 14 Leek R, Harris A. Tumor-associated macrophages in breast cancer.  J Mammary Gland Biol. 2002;  7 177-189
  CrossrefPubMedGoogle Scholar
• 15 Tumminello F M, Badalamenti G, Incorvaia L et al. Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C.  Med Oncol. 2009;  26 10-15
  CrossrefPubMedGoogle Scholar
• 16 Rao V, Dyer C, Jameel J et al. Potential prognostic and therapeutic roles for cytokines in breast cancer.  Oncology Reports. 2006;  15 179-185
  PubMedGoogle Scholar
• 17 Zhang G J, Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma.  Anticancer Res. 1999;  19 1427-1432
  PubMedGoogle Scholar
• 18 Papanicolaou D A, Wilder R L, Manolagas S C et al. The pathophysiologic roles of interleukin-6 in human disease.  Ann Intern Med. 1998;  128 127-137
  CrossrefPubMedGoogle Scholar
• 19 Vidal-Vanaclocha F, Mendoza L, Telleria N et al. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression.  Cancer Metastasis Rev. 2006;  25 417-434
  CrossrefPubMedGoogle Scholar
• 20 Ambrosone C B, Ahn J, Singh K K et al. Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer.  Cancer Res. 2005;  65 1105-1111
  PubMedGoogle Scholar
• 21 Günel N, Coşkun U, Sancak B et al. Clinical importance of serum interleukin-18 and nitric oxide activities in breast carcinoma patients.  Cancer. 2002;  95 663-667
  CrossrefPubMedGoogle Scholar
• 22 Golab J. Interleukin 18 – interferon gamma inducing factor – a novel player in tumour immunotherapy?.  Cytokine. 2000;  12 332-338
  CrossrefPubMedGoogle Scholar
• 23 Okano F, Yamada K. Canine interleukin-18 induces apoptosis and enhances Fas ligand mrNa expression in a canine carcinoma cell line.  Anticancer Res. 2000;  20 3411-3415
  PubMedGoogle Scholar
• 24 Park C C, Morel J C, Amin M A et al. Evidence of IL-18 as a novel angiogenic mediator.  J Immunol. 2001;  167 1644-1653
  PubMedGoogle Scholar
• 25 Pasqualini J R, Cortes-Prieto J, Chetrite G et al. Concentrations of estrone, estradiol and their sulfates, and evaluation of sulfatase and aromatase activities in patients with breast fibroadenoma.  Int J Cancer. 1997;  70 639-643
  CrossrefPubMedGoogle Scholar
• 26 Millington D S. Determination of hormonal steroid concentrations in biological extracts by high-resolution mass fragmentography.  J Steroid Biochem. 1975;  6 239-245
  CrossrefPubMedGoogle Scholar
• 27 Key T, Appleby P, Barnes I et al. The endogenous hormones and breast cancer collaborative study. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective cohort studies.  J Natl Cancer Inst. 2002;  94 606-616
  CrossrefPubMedGoogle Scholar
• 28 Key T J, Chen J, Wang D Y et al. Sex hormones in women in rural China and in Britain.  Br J Cancer. 1990;  62 631-636
  CrossrefPubMedGoogle Scholar
• 29 Berrino F, Pasanisi P, Bellati C et al. Serum testosterone levels and breast cancer recurrence.  Int J Cancer. 2005;  113 499-502
  CrossrefPubMedGoogle Scholar

Prof. Dr. Steffen Albrecht, Laborbereichsleiter

Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden
Anstalt des öffentlichen Rechts des Freistaates Sachsen

Fetscherstraße 74

01307 Dresden

Email: steffen.albrecht@tu-dresden.de